XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Jun. 30, 2020
USD ($)
Apr. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jan. 31, 2020
USD ($)
Aug. 30, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                       $ 236,178 $ 866,863   $ 1,830,639 $ 3,832,442  
Grant funding liability                       8,616,622     8,616,622   $ 6,065,212
ApolloBio | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Territory expansion option period   3 years                              
Proceeds received in upfront payment                   $ 19,400,000              
Upfront payment received                   23,000,000.0       $ 23,000,000.0 23,000,000.0    
Advisory fees                   960,000              
Additional revenue to be achieved                             $ 20,000,000.0    
Royalty period                             10 years    
Period from effective date for termination                             1 year    
Number of days written notice before termination                             90 days    
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Foreign corporate income taxes reducing upfront payment                   2,200,000              
Foreign non-corporate income taxes reducing upfront payment                   $ 1,400,000              
AstraZeneca                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Revenues                       21,000 255,000   $ 167,000 3,000,000.0  
AstraZeneca | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Upfront payment received $ 27,500,000                   $ 27,500,000            
Anticipated development and regulatory event based payment receivable milestones                             125,000,000    
Anticipated commercial event based payment receivable milestones                             115,000,000    
Number of additional products to be developed | product     2                            
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received         $ 6,900,000                        
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever And MERS Vaccine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received         $ 56,000,000                        
Collaborative agreement, period to receive funding for research and development         5 years                        
Grant funding liability                       3,700,000     3,700,000    
Funding received for research and development                       1,600,000 1,500,000   4,600,000 4,600,000  
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received             $ 9,000,000.0                    
Grant funding liability                       1,100,000     1,100,000    
Funding received for research and development                       1,300,000     9,500,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received         $ 5,000,000.0                        
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Collaborative agreement, funding to be received         $ 1,300,000                        
Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Grant funding liability                       703,000     703,000    
Funding received for research and development               $ 1,100,000 $ 2,200,000     164,000 $ 1,500,000   334,000 $ 4,600,000  
Bill And Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Grant funding liability                       3,100,000     3,100,000    
Funding received for research and development           $ 5,000,000.0           943,000     1,900,000    
Department of Defence | Collaborative Arrangement, Product                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Contra-research and development expense                       7,700,000     7,700,000    
Accounts receivable                       $ 7,700,000     $ 7,700,000    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Funding received for research and development       $ 54,500,000                          
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Purchase price, procurement contract       $ 16,600,000